Cardio Diagnostics Holdings, Inc. (CDIO)
| Market Cap | 5.98M -1.2% |
| Revenue (ttm) | 14,450 -25.9% |
| Net Income | -6.47M |
| EPS | -2.76 |
| Shares Out | 2.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,061 |
| Open | 2.000 |
| Previous Close | 2.010 |
| Day's Range | 2.000 - 2.030 |
| 52-Week Range | 0.970 - 7.910 |
| Beta | 2.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About CDIO
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic... [Read more]
Financial Performance
In 2025, CDIO's revenue was $14,825, a decrease of -57.51% compared to the previous year's $34,890. Losses were -$6.50 million, -22.49% less than in 2024.
Financial StatementsNews
Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. will host an investor conference call on Thursday, August 20, 2026, at 3 p.m. Central Time.
Cardio Diagnostics announces AHP to cover Epi+Gen CHD, PrecisionCHD
Cardio Diagnostics (CDIO) Holdings announces that Atlas Healthcare Physicians, AHP, will cover Cardio Diagnostics’ tests, Epi+Gen CHD and PrecisionCHD, for their members with prior authorization begin...
Atlas Healthcare Physicians to Cover Cardio Diagnostics' Precision Cardiovascular Medicine Tests Across Its Network
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced that Atlas Healthcare Physicians (AHP) will cover Cardio Diagnostics' tests, Epi+Gen CHD™ and PrecisionCHD™.
Cardio Diagnostics to showcase cardiovascular solutions at four conferences
Cardio Diagnostics (CDIO) Holdings announced that the company will exhibit at four upcoming national benefits conferences, connecting with employers, brokers, union trustees, and plan administrators o...
Cardio Diagnostics Holdings, Inc. to Showcase Precision Cardiovascular Solutions at Four National Benefits Conferences in June
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will exhibit at four upcoming national benefits conferences.
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Meesha Dogan, CEO of Cardio Diagnostics Holdings Inc.
AUSTIN, Texas, May 20, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the...
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, February 19, 2026
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will host an investor conference call on Thursday, February 19, 2026, at 3 p.m. Central Time.
Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time.
Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics, Aimil Ltd., and Dr. Lal PathLabs announce strategic agreement to launch Cardio Diagnostics' PrecisionCHD™ test in India.
Cardio Diagnostics Holdings, Inc. and Southdale YMCA Announce New Heart Health Partnership to Serve the Edina, Minnesota Community
EDINA, Minn. & CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced a partnership with the Southdale YMCA, becoming the second YMCA location nationally to partner with Cardio Diagnostics.
Cardio Diagnostics gets gapfill payment rate for Epi+Gen, Precision CHD tests
Cardio Diagnostics (CDIO) announced that the Centers for Medicare and Medicaid Services has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD and PrecisionCHD tests. This…
Cardio Diagnostics Receives Final Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that CMS has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD™ and PrecisionCHD™ tests.
Cardio Diagnostics Holdings, Inc. to Present Data Demonstrating PrecisionCHD's Ability to Detect INOCA and MINOCA at the American Heart Association Scientific Sessions
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting new data at the American Heart Association (AHA) Scientific Sessions.
Cardio Diagnostics Holdings, Inc. and YMCA of East Tennessee Partner to Bring Heart Health Education and Advanced Testing to East Tennessee Community
KNOXVILLE, Tenn. & CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced they are partnering with YMCA of East Tennessee to launch a customized program exclusively for its members.
Cardio Diagnostics Holdings, Inc. Expands Provider Network, Adding 15 New Provider Organizations From Across the United States
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. today announced the Company has partnered with 15 new provider organizations across the United States.
Cardio Diagnostics gets CMS gapfill payment rates for cardiovascular tests
Cardio Diagnostics (CDIO) announced that the Centers for Medicare and Medicaid Services, through the MolDX program, has issued preliminary gapfill payment rates of $350 for Epi+Gen CHD and $684.76 for...
Cardio Diagnostics Receives Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics CMS has issued preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™.
Cardio Diagnostics, AGEPHA Pharma in deal for heart disease study
Cardio Diagnostics (CDIO) Holdings and AGEPHA Pharma announced an agreement that will enable the validation of a precision-guided approach to treating inflammation-driven coronary heart disease. AGEPH...
Cardio Diagnostics Enters Into an Agreement with AGEPHA Pharma to Advance Precision Assessment and Management of Inflammation Associated with Coronary Heart Disease
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced an agreement with AGEPHA Pharma.
Cardio Diagnostics secures Japanese patent for set of biomarkers
Cardio Diagnostics (CDIO) announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company’s intellectual property portfolio. The patent is exclusively licensed ...
Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company's IP portfolio.
Cardio Diagnostics regains compliance with Nasdaq
Cardio Diagnostics (CDIO) announced that it received a notification letter from Nasdaq notifying the company that it had regained compliance with the minimum bid price requirement set forth in the…
Cardio Diagnostics Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced it has regained compliance with Nasdaq minimum bid price.
Cardio Diagnostics Broadens Access to Precision Cardiovascular Care with New Practice Partnerships Across U.S. Mainland and Puerto Rico
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has the continued expansion of its reach with a new cohort of healthcare practices across the United States.
Cardio Diagnostics Holdings Inc trading resumes
13:00 EDT Cardio Diagnostics (CDIO) Holdings Inc trading resumes